放射外科
医学
贝伐单抗
胶质母细胞瘤
总体生存率
放射治疗
放射科
肿瘤科
核医学
内科学
化疗
癌症研究
作者
Adomas Bunevičius,Jason P. Sheehan
标识
DOI:10.1016/j.nec.2020.08.007
摘要
Glioblastoma (GBM) is infiltrative neoplasm with limited treatment options and poor overall survival. Stereotactic radiosurgery (SRS) allows spatially precise and conformal delivery of high doses of radiation. Salvage SRS for locally recurrent GBM was shown to improve patient survival and have more favorable safety profile than repeated surgical resection. Boost SRS after fractionated radiation therapy is sometimes attempted; however, Radiation Therapy Oncology Group 93–05 randomized clinical trial did not demonstrate benefits of upfront SRS that was administered before fractionated radiation. Administration of bevacizumab with SRS is associated with improved survival and can allow SRS dose escalation.
科研通智能强力驱动
Strongly Powered by AbleSci AI